
Gwo Xi Stem Cell’s novel stem cell therapy for stroke, GXNPC1®, has had its latest research findings published in the international academic journal The ACTO Times (Vol. 2, Issue 4, Autumn 2025) under the title “Gwo Xi’s stem cell product GXNPC1 shows safety and beneficial effect for stroke patients.”


In clinical practice, Stem Cell Therapy (also known as Regenerative Medicine) involves a treatment process where cells are professionally processed prior to administration. The stem cells must be harvested from the human body and undergo rigorous processing, such as purification, isolation, culture, and quality testing. This meticulous processing ensures the quality of the final cell-based product before it is administered into the patient's body to repair damaged tissues, modulate the immune system, and promote the regeneration of organs and tissues.

In recent years, regenerative medicine has progressed alot. After unveiling stem cells’ regenerative potential, scientists began to explore the beneficial effects of exosome in the field of organ/tissue repair and anti-aging. Because stem cell therapies are costly and risky for the reasons like self-copy and tumorigenesis, exosomes secreted by stem cells, with high safety and biocompatibility profiles, have become a key bridge between regenerative medicine and various industries. Exosomes are constantly discussed and explored in the realm of aesthetic skincare.

Exosomes are nanoscale extracellular vesicles (EVs) secreted by cells, ranging in size from 30 to 150 nanometers (nm). They are commonly found in bodily fluids such as blood, urine, saliva, and others.

Exosome-based hair regrowth takes a different approach. It is minimally invasive and combines tissue repair with follicle activation.




Licensing Transactions are a common collaboration model in the biotech and pharmaceutical industry.

GXNPC1® has demonstrated significant neurological improvement in patients with chronic stroke.

This study showed that the intra-articular administration of GXCPC1®, an allogeneic adipose-derived stem cell, was safe and well-tolerated in subjects with therapeutic alternatives to treat knee osteoarthritis (knee OA) during 1 year follow-up period.

GXHPC1® demonstrated favorable safety and efficacy in its Phase I human clinical trial. No safety concerns were observed during follow-up period, and patients with liver cirrhosis showed a tendency of improvements for liver function, METAVIR score, Child–Pugh score, MELD score, and quality of life.

The results demonstrated that transplantation of hIPCs significantly alleviates hyperglycemia in streptozotocin-induced diabetic rats, offering a promising approach for safe and cost-effective diabetes treatment.

PRFr (GX Factor®) releases abundant of growth factors such as PDGF-AB, IGF-1, and TGF-β1 within 300 minutes, suggesting that GX Factor® can effectively enhance growth factor release and promote wound healing.

In this study, it showed that BP-primed human adipose-derived stem cells (BP-pretreated hADSCs) significantly reduced arrhythmias following myocardial infarction and enhanced the cells’ cardioprotective effects via the PI3K/Akt/GSK-3β pathway.

With advances in medical science, the ways we treat disease are continuously evolving.

INCI name serves as a trusted resource for the cosmetics industry and researchers, helping ensure consumer safety and transparency.